Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.

Systems, Inc. Announces Corporate Name Change

WEST LAFAYETTE, IN, March

19, 2021 - Bioanalytical Systems, Inc. (NASDAQ:BASI) (the "Company", "We", "Our"

or "Inotiv"), a leading provider of nonclinical and analytical contract research services, today announced a change

of the Company's corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc.

The name change was approved

by the Company's shareholders on March 18, 2021, at the Company's annual meeting of shareholders and became effective

as of the filing of articles of amendment to the Company's Second Amended and Restated Articles of Incorporation, as amended,

that same day. Effective Monday, March 22, 2021, The Company's common shares will trade under the ticker symbol "NOTV."

The Company's common shares have been assigned a new CUSIP number of 45783Q 100. The corporate name change to Inotiv, Inc.

does not affect the rights of the Company's shareholders or the number of outstanding common shares and no action is required

by shareholders with respect to the name change, the ticker symbol change or the CUSIP number change.

The corporate name change to

Inotiv, Inc. reinforces the Company's contract research services brand originally launched in November 2019, and represents

the coming together of the Company's legacy contract research services with those acquired in the Seventh Wave Laboratories,

Smithers Avanza Toxicology Services, and Pre-Clinical Research Services acquisitions. The unified Company continues to provide

top-tier in vivo toxicology, pharmacology, drug metabolism, bioanalysis, pathology, pharmacokinetic, and surgical and medical

device discovery and development solutions.

"Since the launch of the

Inotiv brand in 2019, we've worked hard to execute on our growth strategy by strengthening our capabilities, investing in

our service offerings, infrastructure and people, and messaging our Expect More' philosophy to prospects and clients,"

said Company President and Chief Executive Officer Robert Leasure, Jr. "Changing our corporate name was a logical step towards

solidifying our brand and clearly communicating what it reflects- a broadly capable, right-sized CRO with a fundamental

goal of delivering exceptional client experiences."

The Company intends to continue

to operate its research product manufacturing division under the name BASi Research Products.

Inc., is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical

companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing

innovative services supporting its clients' discovery and development objectives for improved decision-making and accelerated

goal attainment. The Company's products focus on increasing efficiency, improving data, and reducing the cost of taking

new drugs to market. Visit inotivco.com for more information about the Company.

release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks

and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales

of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful

closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for

our services and products and our operations, including the measures taken by governmental authorities to address the pandemic,

which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those

detailed in the Company's filings with the U.S. Securities and Exchange Commission.